The optimal DST approach is likely to vary depending on the regimen, patient population, and resources available. The authors in the attached manuscript developed a Markov model to compare options for FQ-DST when introducing a novel, fluoroquinolone-containing treatment regimen for rifampin-susceptible and rifampin-resistant TB, using the BPaMZ drug combination as an illustrative example.
Kendall_2019.pdf (675.6 KB)